AKT1 and Burkitt lymphoma: The capacity to target the PI3K/AKT pathway with small molecule inhibitors in Burkitt’s lymphoma cell lines was investigated by Bhatti et al. [194] who also examined the activation of this pathway in a resistant BL cell line model.